Texas Teachers’ Retirement System buys 1,605 shares of Evolent Health, Inc. (NYSE: EVH)


Teacher Retirement System of Texas increased its position in shares of Evolent Health, Inc. (NYSE: EVHGet a rating) by 9.5% in the first quarter, according to the company in its latest 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,466 shares of the technology company after purchasing an additional 1,605 shares during the period. The Teacher Retirement System of Texas holdings in Evolent Health were worth $596,000 at the end of the most recent reporting period.

A number of other large investors have also recently increased or reduced their stake in the company. AdvisorShares Investments LLC bought a new position in Evolent Health during Q1 worth approximately $192,000. Qube Research & Technologies Ltd increased its stake in Evolent Health shares by 87.3% during the 1st quarter. Qube Research & Technologies Ltd now owns 33,974 shares of the tech company worth $1,097,000 after buying an additional 15,840 shares in the last quarter. Aigen Investment Management LP acquired a new position in Evolent Health stock during Q1 worth approximately $312,000. New York State Common Retirement Fund increased its equity stake in Evolent Health by 1.2% during the first quarter. The New York State Common Retirement Fund now owns 92,651 shares of the technology company worth $2,993,000 after buying 1,055 additional shares in the last quarter. Finally, Advisor Group Holdings Inc. increased its equity stake in Evolent Health by 641.2% during the 1st quarter. Advisor Group Holdings Inc. now owns 30,054 shares of the technology company worth $994,000 after buying 25,999 additional shares in the last quarter. Institutional investors hold 93.27% of the company’s shares.

Insider Trading at Evolent Health

Separately, director Mary Bridget Duffy sold 7,500 shares of the company in a transaction that took place on Tuesday, August 16. The shares were sold at an average price of $33.13, for a total transaction of $248,475.00. Following the transaction, the administrator now directly owns 50,450 shares of the company, valued at $1,671,408.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via the SEC website. In related news, Director Mary Bridget Duffy sold 7,500 shares of Evolent Health in a trade that took place on Tuesday, August 16. The shares were sold at an average price of $33.13, for a total value of $248,475.00. Following the transaction, the administrator now directly owns 50,450 shares of the company, valued at $1,671,408.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this hyperlink. Also, General Counsel Jonathan Weinberg sold 14,335 shares of Evolent Health in a trade that took place on Friday, August 12. The shares were sold at an average price of $34.96, for a total transaction of $501,151.60. Following the completion of the transaction, the General Counsel now directly owns 135,103 shares of the company, valued at $4,723,200.88. Disclosure of this sale can be found here. In the past ninety days, insiders have sold 40,269 shares of the company valued at $1,378,410. 4.20% of the shares are currently held by insiders of the company.

Evolent Health Stock down 0.9%

Shares of EVH opened at $34.68 on Monday. Evolent Health, Inc. has a 12 month minimum of $21.36 and a 12 month maximum of $39.00. The company’s 50-day moving average is $32.35 and its 200-day moving average is $29.78. The stock has a market capitalization of $3.18 billion, a PE ratio of -108.38 and a beta of 1.86. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt ratio of 0.46.

Analyst upgrades and downgrades

A number of stock analysts have recently commented on the stock. Cowen raised his price target on Evolent Health shares to $52.00 in a Monday, July 25 research note. Piper Sandler raised her price target on Evolent Health shares from $35.00 to $40.00 and gave the company an “overweight” rating in a Wednesday, Aug. 3 research note. Royal Bank of Canada raised its target price on Evolent Health shares from $40.00 to $44.00 and gave the company an “outperform” rating in a Wednesday, Aug. 3 research note. Guggenheim raised its price target on Evolent Health shares to $45.00 in a Monday, August 15 research note. Finally, BTIG Research raised its price target on Evolent Health shares from $45.00 to $50.00 and gave the company a “buy” rating in a Wednesday, August 3 research note. One research analyst gave the stock a hold rating and nine gave the company’s stock a buy rating. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.67.

Evolutionary health profile

(Get a rating)

Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.

Read more

Want to see which other hedge funds own EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc. (NYSE: EVHGet a rating).

Institutional ownership by quarter for Evolent Health (NYSE:EVH)



Get news and reviews for Evolent Health Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Evolent Health and related companies with MarketBeat.com’s free daily email newsletter.

About Shirley L. Kreger

Check Also

System-on-chip (SoC) market expected to reach USD 214.8

New York, United States, Sept. 21, 2022 (GLOBE NEWSWIRE) — According to a comprehensive research …